BETHESDA, MD
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE FIBROUS DYSPLASIA FOUNDATION, founded in 2004, is a small nonprofit in the Diseases & Disorders sector that reported $246K in total revenue in fiscal year 2024. Revenue fell 24% from the prior year — a significant decline worth monitoring.
THE FIBROUS DYSPLASIA FOUNDATION SERVES PEOPLE AFFECTED WITH FIBROUS DYSPLASIA/MCCUNE-ALBRIGHT SYNDROME THROUGH PROGRAMS OF RESEARCH, EDUCATION, AWARENESS AND SUPPORT.
RESEARCH PROGRAMS: -IN 2025, TEAM FD/MAS AWARDED TWO RESEARCH GRANTS TOTALING OVER 120,000 TO ADVANCE FD/MAS SPECIFIC RESEARCH: --DR. ARIANE ZAMARIOLI OF RIBEIRAO PRETO MEDICAL SCHOOL RECEIVED...
RESEARCH PROGRAMS: -IN 2025, TEAM FD/MAS AWARDED TWO RESEARCH GRANTS TOTALING OVER 120,000 TO ADVANCE FD/MAS SPECIFIC RESEARCH: --DR. ARIANE ZAMARIOLI OF RIBEIRAO PRETO MEDICAL SCHOOL RECEIVED 40,234.00 FOR HER PROJECT ELUCIDATING A LINK BETWEEN MICROFRACTURES AND FIBROUS DYSPLASIA BONE PAIN IN MICE. --DR. J. SILVIO GUTKIND OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, RECEIVED 80,468.00 FOR HIS PROJECT TARGETING GNAS-DRIVEN PATHWAY FOR PRECISION THERAPY OF FIBROUS DYSPLASIA. -HOSTED TWO RESEARCH UPDATES --DR. MARC WEIN OF MASS GENERAL HOSPITAL SHARED FINDINGS FROM HIS PRMRP- FUNDED PROJECT, FOCUSING ON THERAPEUTIC CONCEPTS THAT HAVE EMERGED FROM HIS BASIC SCIENCE STUDIES. --IN JUNE, ALISON BOYCE SHARED RESEARCH UPDATES FROM HER PHASE TWO CLINICAL TRIAL OF BUROSUMAB, WHICH HELPS REGULATE PHOSPHATE LEVELS -SUPPORT AND MAINTENANCE OF THE FD/MAS PATIENT REGISTRY, AN IRB-APPROVED STUDY.
ADVOCACY PROGRAMS: -ALLIANCE ADVOCATES SECURED ANOTHER YEAR OF ACCESS TO THE PEER-REVIEWED MEDICAL RESEARCH PROGRAM (PRMRP) AND 150 MILLION OF POSSIBLE RESEARCH FUNDS -ADRIENNE MCBRIDE SAT ON THE...
ADVOCACY PROGRAMS: -ALLIANCE ADVOCATES SECURED ANOTHER YEAR OF ACCESS TO THE PEER-REVIEWED MEDICAL RESEARCH PROGRAM (PRMRP) AND 150 MILLION OF POSSIBLE RESEARCH FUNDS -ADRIENNE MCBRIDE SAT ON THE GLOBAL GENES CORPORATE ALLIANCE COMMITTEE THAT DEVELOPED A NEW WHITE PAPER, "EARLY AND OFTEN: REIMAGINING PATIENT COMMUNITY ENGAGEMENT TO IMPROVE CLINICAL TRIALS FEASIBILITY," WHICH SHOWS THE TRANSFORMATIVE ROLE OF PATIENT ADVOCACY ORGANIZATIONS IN RARE DISEASE DRUG DEVELOPMENT. -FACES OF FD/MAS IS AN FD/MAS ALLIANCE VIDEO PROJECT ENVISIONED AND GUIDED BY THE PATIENT ADVISORY COUNCIL (PAC). THE PROJECT AIMS TO CAPTURE THE DIVERSE EXPERIENCES OF THOSE IN THE FIBROUS DYSPLASIA, MCCUNE-ALBRIGHT SYNDROME (FD/MAS) COMMUNITY. VIDEOS WERE RELEASED THROUGHOUT 2024 AND 2025.
EDUCATION PROGRAM: -WE EMPOWER THE FD/MAS COMMUNITY WITH THE BEST EDUCATIONAL RESOURCES AND SHARE THESE RESOURCES ON THE FD/MAS ALLIANCE'S WEBSITE AND YOUTUBE CHANNEL. WE PRODUCE AND SHARE...
EDUCATION PROGRAM: -WE EMPOWER THE FD/MAS COMMUNITY WITH THE BEST EDUCATIONAL RESOURCES AND SHARE THESE RESOURCES ON THE FD/MAS ALLIANCE'S WEBSITE AND YOUTUBE CHANNEL. WE PRODUCE AND SHARE EDUCATIONAL WEBINARS FOR PATIENTS AND CAREGIVERS." -MONTHLY WEB PROGRAMMING, DESIGNED AND HOSTED BY FD/MAS ALLIANCES PATIENT ADVISORY COUNCIL, OFFERS AN OPPORTUNITY FOR PATIENTS AND CAREGIVERS TO CONNECT, SHARE EXPERIENCES, AND ASK QUESTIONS IN A SAFE AND SUPPORTIVE SPACE. THIS YEAR, PROGRAMS COVERED TOPICS FOCUSED ON QUALITY OF LIFE AS WELL AS MEDICAL AND EDUCATIONAL PROGRAMMING: LIVING INDEPENDENTLY WITH FD/MAS NAVIGATING RELATIONSHIPS WITH FD/MAS ENCOURAGING SELF-ADVOCACY TOOLS FOR TOUGH TIMES CLINICAL TRIALS 101 PSYCHOLOGY IN PEDIATRIC CARE
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $245,764 | $322,942 | -0.2% |
| Expenses | $270,098 | $388,138 | -0.3% |
| Net Income | $-24,334 | $-65,196 | -0.6% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ADRIENNE MCBRIDE | EXECUTIVE DI | 40.00 |
Officer
|
$88,857 | $0 | $88,857 |
| ANNE CORVELLE | BOARD PRESID | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| CINDI BRANDT LEVIN | BOARD VICE P | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| CHRISTOPHER GUEST | TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| MALISSA KENNEY | SECRETARY | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| MICHAEL COLLINS | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| JUSTIN COHEN | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| JUSTIN HEALY | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| ERIC CHIEN-WEI LIAO | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| GARY POLLASTRO | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| CARMEL SHEMMESH-RAFALOWSKY | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $245,764 | $270,098 | $243,546 | $-24,334 |
| 2024 | $322,942 | $388,138 | $267,364 | $-65,196 |
| 2023 | $282,768 | $377,909 | $329,399 | $-95,141 |
| 2022 | $397,986 | $376,503 | $427,498 | $21,483 |
| 2021 | $395,077 | $350,971 | $421,680 | $44,106 |
| 2020 | $245,035 | $223,636 | $269,119 | $21,399 |
| 2019 | $210,770 | $295,962 | $158,006 | $-85,192 |
Compare THE FIBROUS DYSPLASIA FOUNDATION with other nonprofits in Maryland and across the country.